Resverlogix will be sponsoring a symposium entitled "Epigenetics: A new pathway to tackle residual risk?" on Saturday August 31 at European Society of Cardiology (ESC) in Paris. I will update the 2019 Potential Events List once we get past AAIC mid-July. Maybe by then Resverlogix will have announced some more events that I may have missed. 

https://pace-cme.org/2019/07/03/epigenetics-a-new-pathway-to-tackle-residual-risk/

Epigenetics: A new pathway to tackle residual risk?

Introduction, Ulf Landmesser, MD, Berlin, Germany

Challenges in targeting residual risk in diabetic patients, post ACS, Peter Libby, MD, Boston, USA

BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk, Wouter Jukema, MD, Leiden, the Netherlands

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition?,Kausik Ray, MD, London, United Kingdom

Resverlogix will also have two other presentations at ESC 2019

Mon Sept 2, 2019, 14:00: BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

Tues Sept 3, 2019, 08:30: Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism